This is a non-core endpoint: only basic statistics are computed.
See its core counterpart CD2_PRIMARY_LYMPHOID_HEMATOPOIETIC_EXALLC for full statistics.
Primary_lymphoid and hematopoietic malignant neoplasms
CD2_PRIMARY_LYMPHOID_HEMATOPOIETIC
lymphoma: A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.
Endpoint definition
↥
FinnGen phenotype data
392423 individuals
Apply sex-specific rule None
392423
Check conditions None
392423
Check pre-conditions, main-only, mode, registry filters None
0 out of 7 registries used, show all original rules.
0
Check minimum number of events None
0
Include endpoints
7814
Remove individuals based on genotype QC
7519
CD2_PRIMARY_LYMPHOID_HEMATOPOIETIC
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
2
First used in FinnGen datafreeze
DF2
No data for upset plot.
No data for upset table.
Similar endpoints
↥List of similar endpoints to
Primary_lymphoid and hematopoietic malignant neoplasms
based on the number of shared cases.
Broader endpoints:
- Primary_lymphoid and hematopoietic malignant neoplasms (controls excluding all cancers)
- Malignant neoplasm (controls excluding all cancers)
- Malignant neoplasm
- Malignant neoplasm, wide definition for exclusion
- Malignant neoplasm, wide definition for exclusion (controls excluding all cancers)
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 7519 | 3213 | 4306 |
| Unadjusted prevalence (%) | 1.99 | 1.52 | 2.59 |
| Mean age at first event (years) | 60.99 | 58.32 | 62.98 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_PRIMARY_LYMPHOID_HEMATOPOIETIC – Primary_lymphoid and hematopoietic malignant neoplasms
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Primary_lymphoid and hematopoietic malignant neoplasms
↥Endpoint not on priority list, no data to show.